Gut dysbiosis, including reduced abundance of short-chain fatty acid (SCFA; e.g., butyrate)-producing bacteria, is linked with obesity and metabolic dysfunction. Consistent with this, our recent meta-analysis highlighted that increasing SCFA concentrations in the gut (and/or circulation) improves insulin sensitivity (1). Here, we investigated whether sodium butyrate (NaB) ameliorates diet-induced metabolic dysfunction through gut microbiome modulation and epigenetic regulation of intestinal GLP1 (proglucagon/GCG) gene expression, and whether diet-induced fluctuations in microbial butyrate availability during weight-cycling alters these effects.
Anaerobically maintained human faecal cultures with 10mM NaB for 20-h resulted in reduced Simpson diversity and altered relative abundances of Romboutsia, Eggerthellaceae, Gordonibacter, Lachnoclostridium, and Paraclostridium. Next, we found that 4-day 10mM NaB exposure to human colonic epithelial cells resulted in increased GCG and reduced HDAC1, HDAC6, and HDAC7 transcript expression. Concurrently, we found increased histone H3+H4 acetylation and reduced H3K9 tri-methylation at the GCG promoter region. Interestingly, in cells exposed to oscillating NaB, as may occur during weight-cycling, the amplitude of GCG transcriptional response progressively declined, potentially indicating a shift towards a less active chromatin state. Furthermore, oscillating (high)-fat-diet (HFD)/chow and cafeteria (CAF)/chow diets resulted in equally decreased faecal SCFA and adverse metabolic outcomes compared to continuous HFD/CAF control mice.
In 60% HFD-fed mice, 4-day NaB infusion (0.11µL/min) into the proximal colon reversed gut dysbiosis and improved glucose clearance. Furthermore, following a metabolic dysfunction induction period (4-week CAF diet feeding, better reflective of Western diet variety and palatability compared to HFD (2)), 7-week 100mM NaB drinking water supplementation attenuated both CAF-induced fasting hyperglycaemia and percentage weight gain in male mice. Endpoint (23-week) glucose and insulin tolerance, serum GLP-1, behavioural outcomes, faecal microbial profile and colonic GCG promoter chromatin analyses will be presented.
These findings support a model in which butyrate reverses metabolic disease through complementary microbial and epigenetic mechanisms, with fluctuating butyrate availability influencing intestinal GCG responsiveness and downstream metabolic signalling.